Table 2.
Clinical characteristics and CD4+Foxp3+ lymphocytes of uveitis patients
| Patient No |
Age | Gen der |
Diagnosis | Laterality | VA OD |
VA OS |
Systemic vs. ocular |
Active vs. inactive |
CME | CD4+Foxp3+ lymphocytes (cells/uL) |
%CD4+Foxp3 + lymphocytes |
Medications |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 35 | M | Scleritis, panuveitis, Wegener's granulomatosis | U/L | 20/160 | 20/20 | Systemic | Active | Y | 93 | 0.95% | CSA 125 mg bid, INFLIX 8 mg/kg, Pred 40 mg/day |
| 2 | 22 | F | Panuveitis, sarcoidosis | B/L | 20/40 | 20/100 | Systemic | Active | Y | 75 | 0.56% | Pred 20 mg/day, MTX 20 mg/wk |
| 3 | 20 | F | Idiopathic granulomatous panuveitis | B/L | 20/500 | 20/640 | Ocular | Active | Y | 110 | 5.20% | MMF 1000 bid, Pred 20 mg/day, Dac 2 mg/kg/mo |
| 4 | 48 | F | Panuveitis, sarcoidosis | B/L | 20/63 | 20/50 | Systemic | Active | N | 178 | 3.66% | MMF 1000 bid, MTX 15 mg/wk |
| 5 | 43 | F | Intermediate uveitis | U/L | 20/32 | 20/12. 5 | Ocular | Active OD | Y | 308 | 5.96% | MTX 22.5 mg/wk |
| 6 | 58 | F | Intermediate uveitis | B/L | 20/125 | 20/125 | Ocular | Active OD | N | 419 | 3.39% | None |
| 7 | 22 | F | Intermediate uveitis, non- specific CTD, Pulmonary fibrosis, pericardial effusion | B/L | 20/40 | 20/125 | Systemic | Active | Y | 820 | 7.62% | Pred 20 mg/day |
| 8 | 61 | F | Intermediate uveitis, MS- associated | B/L | 20/200 | 20/800 | Systemic | Active | Y | 526 | 4.90% | Pred 17.5 mg/day, Dac 1 mg/kg/mo |
| 9 | 35 | F | Multifocal choroiditis/Punctate inner choroidopathy | B/L | 20/12.5 | 20/80 | Ocular | Inactive | N | 487 | 9.52% | SIR 2 MG qod |
| 10 | 31 | F | Multifocal choroiditis/Punctate inner choroidopathy | B/L | 20/20 | 20/20 | Ocular | Inactive | N | 645 | 5.40% | None |
| 11 | 45 | M | Multifocal choroiditis | B/L | 20/63 | 20/50 | Ocular | Inactive | N | 790 | 15.10% | None |
| 12 | 49 | F | Panuveitis, sarcoidosis | B/L | 20/100 | 20/20 | Systemic | Inactive | N | 147 | 4.33% | Dac 1 mg/kg |
| 13 | 51 | M | Panuveitis, Vogt-Koyanagi- Harada's disease | B/L | 20/25 | 20/40 | Systemic | Inactive | N | 120 | 2.93% | MMF 1000 bid, Pred 11 mg/day, Dac 2 mg/kg/mo |
| 14 | 46 | F | Intermediate uveitis, sarcoidosis | B/L | 20/20 | 20/20 | Systemic | Inactive | N | 471 | 6.19% | Prednisone 5 mg/day |
| 15 | 26 | M | Panuveitis with vasculitis, Behcet's disease | B/L | 20/400 | 20/320 | Systemic | Inactive | Y | 162 | 6.80% | MMF 750 bid, CSA 200 bid, Pred 16 mg/day |
| 16 | 46 | F | Intermediate uveitis, sarcoidosis | B/L | 20/20 | 20/20 | Systemic | Inactive | N | 471 | 6.19% | Pred 5 mg/day |
| 17 | 56 | F | Birdshot retinochoroidopathy | B/L | 20/32 | 20/20 | Ocular | Inactive | Y | 568 | 5.62% | MMF 1000 bid, CSA 100 bid, Pred 15 mg/day, Dac 2 mg/kg/mo |
| 18 | 52 | F | Intermediate uveitis | B/L | 20/100 | 20/63 | Ocular | Inactive | N | 512 | 6.82% | None |
| 19 | 52 | F | Intermediate uveitis | B/L | 20/32 | 20/20 | Ocular | Inactive | N | 300 | 18.00% | MTX 7.5 mg/wk |
| 20 | 15 | M | Intermediate uveitis | B/L | 20/60 | 20/40 | Ocular | Inactive | N | 182 | 5.40% | CSA 225 bid |
Abbreviations: CSA Cyclosporin, MMF Mycophenolate mofetil, MTX Methotrexate, SIR Sirolimus, INFLIX Infliximab, Pred Prednisone, Dac Daclizumab, CTD Connective tissue disease, MS Multiple sclerosis